ProShares Ultra Nasdaq Biotechnology (BIB)
59.22
+1.18
(+2.03%)
USD |
NASDAQ |
Dec 06, 16:00
60.00
+0.78
(+1.32%)
Pre-Market: 08:52
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
-- | -- | -- | -- |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
-- | Upgrade | -- | Upgrade |
Basic Info
Investment Strategy | |
General | |
Security Type | |
Equity Style | |
Fixed Income Style | |
Broad Asset Class | |
Broad Category | |
Category Name | |
Category Index | |
Global Category Name | |
YCharts Categorization | Alts |
YCharts Benchmark | Private Equity Index Total Return (^PEATR) |
Prospectus Objective | |
Fund Owner Firm Name |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | 200.0% |
Broad Asset Class Benchmark Index | |
100.0% | |
Manager Tenure | |
Michael Neches | 11.17 yrs |
Tarak Davé | 6.59 yrs |
Performance Versus Category
Annual Total Returns Versus Peers
As of December 09, 2024.
Asset Allocation
Type | % Net | % Long | % Short |
---|---|---|---|
Cash | -- | -- | -- |
Stock | -- | -- | -- |
Bond | -- | -- | -- |
Convertible | -- | -- | -- |
Preferred | -- | -- | -- |
Other | -- | -- | -- |
Basic Info
Investment Strategy | |
General | |
Security Type | |
Equity Style | |
Fixed Income Style | |
Broad Asset Class | |
Broad Category | |
Category Name | |
Category Index | |
Global Category Name | |
YCharts Categorization | Alts |
YCharts Benchmark | Private Equity Index Total Return (^PEATR) |
Prospectus Objective | |
Fund Owner Firm Name |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | 200.0% |
Broad Asset Class Benchmark Index | |
100.0% | |
Manager Tenure | |
Michael Neches | 11.17 yrs |
Tarak Davé | 6.59 yrs |